JACKSONVILLE, Fla., Nov. 17, 2016 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will deliver a corporate presentation at the Biotech and Money Investival Showcase on Friday, November 18, at 11:30 a.m. (GMT). The conference will take place at the Waldorf Hilton Hotel London, Aldwych, London WC2B 4DD.
Dr. Bonfiglio will speak about TapImmune and its accomplishments and progress. He will focus on the company-sponsored Phase 2 trial in triple-negative breast cancer now enrolling at nine sites, the status of the Phase 2 trial in triple negative breast cancer sponsored by the Mayo Clinic with a grant from the Department of Defense and the ongoing trial with Memorial Sloan Kettering and AstraZeneca in ovarian cancer. In addition, Dr. Bonfiglio will address the recent uplisting of the company to the NASDAQ and future clinical development plans.
Company management will be at the meeting. Conference attendees seeking a one-on-one meeting with Dr. Bonfiglio and Dr. Glynn Wilson, Chairman and CEO, may contact Biotech and Money Investival Showcase.
About TapImmune Inc. TapImmune Inc. is an immuno-oncology company specializing in the development of innovative technologies for the treatment of cancer, including metastasis, and infectious disease. The Company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients' killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The Company's technologies may be used as stand-alone medications or in combination with current treatment modalities.
Forward-Looking Statement Disclaimer This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.